🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ICYMI at #AUA25 - be sure to add your name to the Society of Urologic Oncology speakers bureau, so we can: 💡highlight the expertise of SUO members 📣 promote educational opportunities across the field of urologic oncology Application here ➡️ app.smartsheet.com/b/form/beb85d3…

📺 Dr. Sia Daneshmand, M.D. moderates a new roundtable series featuring guest panelists Mark Tyson, Aaron Berger, MD, of Associated Urological Specialists, and Vignesh Packiam, MD discussing the evolving treatment and diagnostic landscape of #NMIBC: buff.ly/UbJobkE ⭐ In part 1, the panelists

Inspiring story of two bladder cancer survivors helping others through their journey through Bladder Cancer Advocacy Network. Proud to see our very own Dr. Kathryn Marchetti and her research featured in this important story! #BladderCancerAwarenessMonth TribLIVE.com 🧡🔗bit.ly/44ATk3w

Take Action with the Amer. Urol. Assn. to support federal funding for Kidney Cancer and Bladder Cancer! Make your voices heard on behalf of patients and physicians. votervoice.net/AUA/campaigns/…

BCG Shortage Warrants Treatment Shifts, New Treatment Strategies in Bladder Cancer Bogdana Schmidt MD, MPH Huntsman Cancer Institute #BladderCancerAwarenessMonth #BladderCancer onclive.com/view/bcg-short…

Manish Kohli, MD and Joseph Finkelstein, MD, PhD, are exploring how virtual reality can enhance cancer rehab. In an ongoing clinical trial, they’re testing a VR tool that links a patient’s exercise routine to a virtual racetrack. bit.ly/3S0tKgP

Elliot Asare, MD, MS, CMQ, FACs, discusses advancements in skin cancer research, the challenges of accessing care for rural patients, and how telehealth is improving that access. #SkinCancerAwareness Huntsman Cancer Institute University of Utah Health Watch the full interview: youtu.be/GdHsfGofSDU?si…

Dr. Clinton and Dr. Pietzak discussed the management of BCG-refractory NMIBC and highlighted recent BCG and gemcitabine clinical trials as well as new non-BCG therapies #BladderCancerAwarenessMonth #URO64 open.spotify.com/episode/06TDJe…

The evolving treatment landscape for #NMIBC beyond BCG. Bogdana Schmidt MD, MPH Huntsman Cancer Institute joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center in discussing new frontiers in NMIBC: intravesical combos, FGFR3-targeted agents & patient-centered alternatives to radical cystectomy. #WatchNow >

This is an important time point to distinguish routine screening PSA vs a PSA checked for cause (urinary symptoms). A risk assessment and shared decision making with the patient is pertinent but perhaps John Leppert is right - guidance on the matter at large is timely

Thank you Ashish M. Kamat, MD, MBBS for leading a great tumor board and Urology Times for the opportunity to have this conversation! Huntsman Cancer Institute YUO Bladder Cancer Advocacy Network

Experts Spotlight Noteworthy GU Cancer Abstracts Ahead of the 2025 ASCO Annual Meeting Pedro C Barata, MD MSc FACP Stephanie Berg Matt Galsky Bogdana Schmidt MD, MPH Michael Serzan, MD University Hospitals Dana-Farber Icahn School of Medicine at Mount Sinai Mount Sinai Health System UT Southwestern Medical Center University of Utah ASCO #kcsm #pcsm #blcsm onclive.com/view/experts-s…

Treatment options for de novo metastatic hormone-sensitive #ProstateCancer. Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute joins Zach Klaassen Georgia Cancer Center in a case-based discussion Dr. Agarwal emphasizes the importance of treatment intensification beyond ADT monotherapy, which remains

Neeraj Agarwal, MD, FASCO amazing tweets on ASCO #ASCO25 makes it almost unnecessary to go to the meeting this year. I have read almost everything in advance. Add on UroToday.com and basically the meeting is on my phone. Thanks 🙏 Great work!

In SWOG Cancer Research Network 1605, utDNA (UroAmp) predicted response to Atezo in BCG-u #bladdercancer. Baseline and 3 mo positivity linked to lower CR and EFS. A step toward biomarkers-driven bladder sparing care. Marie-Pier St-Laurent Peter Black Parminder singh

In our latest SWIU collaboration, Dr. Linda Shortliffe joins Dr. Martha K. Terris MD to share her path as the first woman to chair a major urology program #URO234 Kathleen Kobashi Cheryl Lee Dr.Larissa Rodriguez Kirsten Greene Polina Reyblat open.spotify.com/episode/6WplmH…

🧬 Our study on molecular profiling of 99 cases of micropapillary urothelial carcinoma (MPUC): • Most common mutations: TP53, TERT, ARID1A, ERBB2 • ERBB2 alterations in 24%: Amplifications, Missense mutations (most common: p.S310F) • Only ERBB2 amplifications associated with:

Gear up for BackTable Tumor Board Season 2: Genitourinary (GU) Cancer! 🚀Launch day is May 27! 🎧11 total in-depth episodes 🔬Multidisciplinary experts from #UroOnc, #MedOnc, #RadOnc, etc. Rich Matulewicz Nabil Adra Viraj Master Bogdana Schmidt MD, MPH Andrea Apolo, M.D. Patrick Hensley, MD

At #ASCO25 : New Nectin4/PD1 combo data with response rates similar to EVP in bladder cancer. Also DV/toripalimab is better than chemo (press release). There multiple ways of beating 1st line chemo in UC. As chemo becomes less relevant a key question is around ADC sequencing

#ASCO25 officially kicks off this week! Ahead of the meeing, we spoke with several experts from the #GU cancer landscape about the abstracts they're anticipating the most. Pedro C Barata, MD MSc FACP Stephanie Berg Matt Galsky Bogdana Schmidt MD, MPH Michael Serzan, MD Read it all here: hubs.li/Q03pdg_H0